Table 3.
Correlation between the results of mutational analysis in FNA samples and outcome in specific groups of indeterminate cytology
| AUS/FLUS (n = 247)a | |||
| Histology Malignant (n = 35) | Histology Benign (n = 212) |
Sensitivity, 63% | |
| Specificity, 99% | |||
| Mutation Positive (n = 25) |
16 RAS (16 fvPTC) | 3 RAS (3 FA) | PPV, 88% |
| 5 BRAF (4 fvPTC) | NPV, 94% | ||
| 1 PAX8/PPARg (1 fvPTC) | Accuracy, 94% | ||
| Mutation Negative (n = 222) |
13 (11 fvPTC, 2 PTC) | 209 (166 NH, 42 FA) | |
| FN or Hürthle Cell Neoplasm/Suspicious for FN (n = 214)b | |||
| Histology Malignant (n = 58) | Histology Benign (n = 156) |
Sensitivity, 57% | |
| Specificity, 97% | |||
| Mutation Positive (n = 38) |
2 BRAF (1 PTC, 1 fvPTC) | 5 RAS (5 FA) | PPV, 87% |
| 29 RAS (21 fvPTC, 5 PTC, 3 FTC) |
NPV, 86% | ||
| Accuracy, 86% | |||
| 2 PAX8/PPARg (2 fvPTC) | |||
| Mutation Negative (n = 176) |
25 (16 fvPTC, 3 PTC, 6 FTC) | 151 (95 HN, 56 FA) | |
| Suspicious for Malignant Cells (n = 25)c | |||
| Histology Malignant (n = 28) | Histology Benign (n = 24) |
Sensitivity, 68% | |
| Specificity, 96% | |||
| Mutation Positive (n = 20) |
10 BRAF (10 PTC) | 1 RAS (1 FA) | PPV, 95% |
| 7 RAS (6fvPTC, 1 FTC) | NPV, 72% | ||
| 1 PAX8/PPARg (1 FTC) | Accuracy, 81% | ||
| 1 RET/PTC (1 PTC) | |||
| Mutation Negative (n = 32) |
9 (7 PTC, 2 fvPTC) | 23 (17 HN, 6 FA) | |
Abbreviation: HN, hyperplastic nodule.
a
Molecular testing reduced observed malignant frequency from 16% to 6%.
b
Molecular testing reduced observed malignant frequency from 27% to 14%.
c
Molecular testing reduced observed malignant frequency from 54% to 28%.